Gilead Q3 EPS Beats by $0.31 on $7.77B Sales, Guides FY25 EPS to $8.05–8.25
Gilead posted Q3 EPS of $2.47, beating forecasts by $0.31 on $7.77 billion revenue (+3% YoY), and issued FY25 EPS guidance of $8.05–8.25. Bank Pictet & Cie Europe AG boosted its stake by 502.8% to 15,288 shares worth $1.697 million, while institutional ownership reached 83.7%.
1. Bank Pictet & Cie Europe AG Significantly Increases Position
In the third quarter, Bank Pictet & Cie Europe AG boosted its stake in Gilead Sciences by 502.8%, acquiring 12,752 additional shares to reach a holding of 15,288 shares. As of the latest SEC filing, this position carried a value of $1,697,000. The move underscores growing institutional confidence, joining substantial purchases by Invesco Ltd., which added 3.39 million shares in the second quarter, and Jump Financial LLC’s new $6.99 million position. Overall, institutional investors now control 83.67% of Gilead’s outstanding shares.
2. Q3 Financial Results Exceed Expectations; FY 2025 Outlook Raised
Gilead reported third-quarter revenue of $7.77 billion, surpassing consensus estimates by $350 million, while adjusted EPS of $2.47 topped projections by $0.31. Year-over-year revenue growth of 3.0% was driven by continued strength in antiviral therapies and expanding oncology franchise sales. The company’s return on equity reached 51.86%, and net margin stood at 27.88%. Management issued full-year 2025 EPS guidance of 8.05 to 8.25, up from prior guidance of 7.90 to 8.10, reflecting anticipated benefits from recent therapy launches and cost optimization initiatives.
3. Analysts Lift Price Targets and Maintain Positive Ratings
Since early September, five major research firms have revised their outlooks on Gilead. Citigroup and Rothschild & Co Redburn each raised their price targets by $10 to $135 and $153 respectively, while DBS Bank upgraded the stock to ‘moderate buy.’ Scotiabank initiated coverage with a ‘sector outperform’ recommendation, and Goldman Sachs reaffirmed a neutral stance but increased its target by $2. Collectively, 22 analysts rate the shares as Buy, two as Strong Buy and four as Hold, yielding an average consensus target implying high single-digit upside.
4. Dividend Hike and Insider Dispositions Highlight Capital Allocation
On December 30th, Gilead paid a quarterly dividend of $0.79 per share, representing an annualized yield of 2.6% and a payout ratio of 48.99%. The ex-dividend date was December 15th, reinforcing the company’s commitment to returning cash to shareholders. In parallel, insiders sold a combined 8,000 shares at prices averaging approximately $123, reducing holdings by up to 36% in certain cases. Over the past quarter, total insider sales amounted to 136,257 shares valued at $16.86 million, reflecting routine liquidity management rather than strategic repositioning.